Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Add To Watchlist

Recent & Breaking News (NDAQ:HALO)

Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics

PR Newswire February 17, 2015

Halozyme Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors

PR Newswire January 21, 2015

Halozyme Therapeutics Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference

PR Newswire January 12, 2015

Halozyme Provides Agenda Highlights For Analyst And Investor Meeting

PR Newswire January 7, 2015

Halozyme Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference

PR Newswire January 6, 2015

Halozyme Therapeutics Appoints Athena Countouriotis, M.D. as Chief Medical Officer

PR Newswire January 5, 2015

Halozyme Therapeutics To Host Analyst And Investor Meeting

PR Newswire December 30, 2014

Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

PR Newswire December 19, 2014

Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE(TM) Technology

PR Newswire December 17, 2014

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

PR Newswire December 12, 2014

Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference

PR Newswire November 25, 2014

Halozyme Reports Third Quarter 2014 Financial Results

PR Newswire November 10, 2014

Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference

PR Newswire November 5, 2014

Halozyme to Host Third Quarter 2014 Financial Results Conference Call

PR Newswire November 3, 2014

Baxter Launches HYQVIA in the United States for Adult Patients with Primary Immunodeficiency

Business Wire October 20, 2014

Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant

PR Newswire October 20, 2014

Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences

PR Newswire October 9, 2014

Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20

PR Newswire October 7, 2014

Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

PR Newswire October 3, 2014

SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer

PR Newswire September 18, 2014